Superannuation funds which fail the Your Future, Your Super (YFYS) performance test should be pulled from the market, according to Stockspot.
In a submission to the Treasury’s YFYS consultation, the firm said other sectors would immediately have products recalled if they failed to meet their requirements.
However, for super funds, failure of YFYS only saw the fund closed to new members while existing members remained invested.
“In any other category (for example, medication) failing a performance test of this nature would lead to the product being recalled or pulled from the market.
“The fact that a significant amount of money has remained in these underperforming funds shows that there is a clear market failure. Super is not a category where consumers are making an informed choice. Members will often stay in a dud product due to a combination of confusion, friction or apathy.”
The view of Stockspot, which recently published its annual performance stats for super funds, was that products which failed twice should be permanently shut and members provided a tax-beneficial option to transfer to another fund.
“The current measures have been effective but there should be a stronger deterrent for underperformance.”
If the test was extended and improved in the future, Stockspot recommended members should be able to compare MySuper products, diversified choice products within risk categories and single asset funds covering major asset classes.
Jim Chalmers has defended changes to the Future Fund’s mandate, referring to himself as a “big supporter” of the sovereign wealth fund, amid fierce opposition from the Coalition, which has pledged to reverse any changes if it wins next year’s election.
In a new review of the country’s largest fund, a research house says it’s well placed to deliver attractive returns despite challenges.
Chant West analysis suggests super could be well placed to deliver a double-digit result by the end of the calendar year.
Specific valuation decisions made by the $88 billion fund at the beginning of the pandemic were “not adequate for the deteriorating market conditions”, according to the prudential regulator.